Literature DB >> 23110537

Comparison of X-chromosome inactivation in Duchenne muscle/myocardium-manifesting carriers, non-manifesting carriers and related daughters.

E Viggiano1, E Picillo, A Cirillo, L Politano.   

Abstract

Female carriers of Duchenne muscular dystrophy (DMD) are usually asymptomatic. However, 2.5-7.8% of them may present muscle symptoms and cardiomyopathy, attributed to a reduced production of dystrophin, probably because of skewed patterns of X-chromosome inactivation (XCI). To evaluate the role of XCI in symptomatic (at muscle or heart level) and asymptomatic DMD carriers, 44 subjects were selected from our database (12 manifesting, 21 non-manifesting, 11 healthy females), and XCI pattern determined in the lymphocytes by the androgen receptor methylation-based assay. The results showed that DMD-manifesting carriers had a preferential inactivation of the X-chromosome carrying the normal allele, while non-manifesting carriers and healthy females showed a random XCI pattern. Moreover, when comparing muscle with heart manifesting carriers, the former group showed a higher degree of skewing. No concordance in XCI was found between mothers and daughters, when symptomatic/asymptomatic mother-daughter pairs were analyzed. The results confirm that DMD clinical manifestations in carriers are associated with non-random patterns of X inactivation.
© 2012 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DMD carriers; Dystrophin gene; Skewed X-inactivation; X-inactivation

Mesh:

Substances:

Year:  2012        PMID: 23110537     DOI: 10.1111/cge.12048

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

1.  Genomic analysis identifies candidate pathogenic variants in 9 of 18 patients with unexplained West syndrome.

Authors:  Naomi Hino-Fukuyo; Atsuo Kikuchi; Natsuko Arai-Ichinoi; Tetsuya Niihori; Ryo Sato; Tasuku Suzuki; Hiroki Kudo; Yuko Sato; Tojo Nakayama; Yosuke Kakisaka; Yuki Kubota; Tomoko Kobayashi; Ryo Funayama; Keiko Nakayama; Mitsugu Uematsu; Yoko Aoki; Kazuhiro Haginoya; Shigeo Kure
Journal:  Hum Genet       Date:  2015-04-16       Impact factor: 4.132

Review 2.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

3.  Clonazepam as an Effective Treatment for Epilepsy in a Female Patient with NEXMIF Mutation: Case Report.

Authors:  Masashi Ogasawara; Eiji Nakagawa; Eri Takeshita; Kohei Hamanaka; Satoko Miyatake; Naomichi Matsumoto; Masayuki Sasaki
Journal:  Mol Syndromol       Date:  2020-09-01

Review 4.  Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series.

Authors:  Andrea Antonio Papa; Paola D'Ambrosio; Roberta Petillo; Alberto Palladino; Luisa Politano
Journal:  Intractable Rare Dis Res       Date:  2017-05

Review 5.  Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy.

Authors:  Emanuela Viggiano; Manuela Ergoli; Esther Picillo; Luisa Politano
Journal:  Hum Genet       Date:  2016-04-21       Impact factor: 4.132

6.  Gene Editing for the Heart: Correcting Dystrophin Mutations.

Authors:  Elizabeth M McNally
Journal:  Circ Res       Date:  2017-09-29       Impact factor: 17.367

7.  Impact of estrogen deficiency on diaphragm and leg muscle contractile function in female mdx mice.

Authors:  Pangdra Vang; Cory W Baumann; Rebecca Barok; Alexie A Larson; Brendan J Dougherty; Dawn A Lowe
Journal:  PLoS One       Date:  2021-03-31       Impact factor: 3.240

8.  Pregnancy-induced amelioration of muscular dystrophy phenotype in mdx mice via muscle membrane stabilization effect of glucocorticoid.

Authors:  Yuko Shimizu-Motohashi; Yoko Asakura; Norio Motohashi; Nandkishore R Belur; Michael G Baumrucker; Atsushi Asakura
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  X-Linked Emery-Dreifuss Muscular Dystrophy: Study Of X-Chromosome Inactivation and Its Relation with Clinical Phenotypes in Female Carriers.

Authors:  Emanuela Viggiano; Agnieszka Madej-Pilarczyk; Nicola Carboni; Esther Picillo; Manuela Ergoli; Stefania Del Gaudio; Michal Marchel; Gerardo Nigro; Alberto Palladino; Luisa Politano
Journal:  Genes (Basel)       Date:  2019-11-11       Impact factor: 4.096

10.  Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up.

Authors:  Amir Dori; Michela Guglieri; Marianna Scutifero; Luigia Passamano; Antonio Trabacca; Luisa Politano
Journal:  Acta Myol       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.